Leadless Pacemakers Marke (2026-2036)

The growth of this market is mainly driven by the complications associated with transvenous leads and surgical pockets in conventional pacemakers, the aging of populations and rising prevalence of bradyarrhythmias, the arrival of dual-chamber leadless pacing, and a growing body of clinical evidence supporting leadless devices. However, the higher cost of leadless devices relative to conventional pacemakers, historical limitations in pacing modes, procedural risks such as cardiac perforation, and uncertainty over long-term device management and retrieval restrain the growth of this market.

Furthermore, modular systems that combine leadless pacing with other cardiac devices, leadless cardiac resynchronization and conduction system pacing, and expansion into emerging markets are expected to offer growth opportunities for the stakeholders in this market. However, implanter training and the learning curve, battery longevity and the management of multiple devices over a patient's lifetime, competition from conduction system pacing with conventional leads, and access and affordability in price-sensitive markets remain major challenges impacting the growth of this market. Additionally, the shift toward dual-chamber leadless pacing, retrievability and lifetime device management, miniaturization and extended battery life, and the development of communicating multi-device ecosystems are prominent trends in this market.

The Leadless Pacemakers Market comprises self-contained cardiac pacemakers, integrating the battery, electronics, and electrodes in a capsule, that are implanted directly inside the heart through a catheter introduced via the femoral vein, eliminating the transvenous leads and subcutaneous pocket required by conventional pacemakers. The market covers single-chamber leadless pacemakers placed in the right ventricle or right atrium, dual-chamber and atrioventricular-synchronous leadless systems, modular systems that communicate with other implanted devices such as subcutaneous implantable cardioverter-defibrillators, and leadless cardiac resynchronization systems that pace the left ventricle from inside the heart. Devices are distinguished by fixation mechanism, such as nitinol tines or an active helix, battery longevity, retrievability, and communication capability. Indications include atrioventricular block, sick sinus syndrome, atrial fibrillation with slow ventricular response, and heart failure requiring resynchronization. Market value is measured at manufacturer sales of devices and delivery systems. Conventional transvenous pacemakers are excluded. The ecosystem spans device manufacturers, component and battery suppliers, electrophysiologists and cardiologists, hospitals and cardiac centers, payers, and regulators.

Pacemakers are among the most widely used cardiac devices, with nearly 1 million people worldwide receiving a pacemaker each year, and leadless pacing represents one of the most significant advances in the technology since the first implantable pacemakers. Medtronic's Micra became the first leadless pacemaker approved by the FDA in April 2016, and when Medtronic announced FDA approval of its next-generation Micra AV2 and Micra VR2 systems, which received CE Mark in January 2024, it reported that nearly 200,000 patients globally had received a Micra device. Abbott's AVEIR VR, approved by the FDA in April 2022 based on the LEADLESS II investigational device exemption study, added a mapping capability allowing physicians to measure electrical signals before final fixation and a design intended for retrieval.

Dual-chamber leadless pacing has expanded the addressable population. Abbott's AVEIR DR system combines the AVEIR VR ventricular device with the AVEIR AR atrial device, using Abbott's i2i implant-to-implant technology, which transmits high-frequency pulses through the blood to synchronize the two pacemakers beat-to-beat while using far less battery current than radiofrequency or Bluetooth communication, and Abbott noted that more than 80% of people requiring pacing need pacing in both the right atrium and right ventricle. Abbott launched AVEIR DR in markets including India in October 2025. Boston Scientific is developing the EMPOWER leadless pacemaker, designed to communicate with its subcutaneous implantable cardioverter-defibrillator, and EBR Systems' WiSE system provides leadless endocardial left ventricular pacing for cardiac resynchronization therapy.

Leadless pacemakers address well-known complications of conventional systems, including lead fractures, lead dislodgement, venous obstruction, and pocket infections and hematomas, and a Micra post-approval registry of 795 patients at 97 centers reported a 99.6% implant success rate and a 1.5% major complication rate at 30 days. However, leadless devices cost more than conventional pacemakers, carry a risk of cardiac perforation during implantation, and raise questions about long-term management when batteries are depleted. With the World Health Organization projecting that one in six people worldwide will be aged 60 or older by 2030, and with dual-chamber, modular, and resynchronization capabilities broadening eligibility, the market is expected to grow substantially through 2036.